---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-008977"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-01-28T23:59:59+00:00"
generated_at: "2026-06-27T14:27:37.135237+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Celldex amends bylaws to implement proxy access for shareholders

## Summary
- Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.
- Stockholders or group owning at least 3% of stock continuously for 3 years may nominate directors.
- Maximum nominees is greater of 2 individuals or 20% of board, subject to requirements.
- Proxy access will first apply for the 2023 annual meeting of shareholders.
- Full amendment text filed as Exhibit 3.1 to this 8-K.

## SEC filing metadata
- accession: 0001104659-22-008977
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-01-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/0001104659-22-008977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/tm224432d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-008977
- JSON: https://secwatch.observer/filing/0001104659-22-008977.json
- Plain text: https://secwatch.observer/filing/0001104659-22-008977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.